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Summary
Objectives: To define the maximum tolerated dose (MTD), the
toxicity and pharmacokinetic profile of BBR3464, a novel
triplatinum complex.
Patients and methods: Fourteen patients with advanced
solid tumors not responsive to previous antitumor treatments
received BBR 3464 on a daily x 5 schedule every twenty-eighth
day. The drug was given as a one-hour infusion with pre-and
post-treatment hydration (500 ml in one hour) and no antiemetic
prophylaxis. The starting dose was 0.03 mg/m2/day. A modi-
fied accelerated titration escalation design was used. Total and
free platinum (Pt) concentrations in plasma and urine were
assessed by ICP-MS on days 1 and 5 of the first cycle.
Results: Dose was escalated four times up to 0.17 mg/nr/day.
Short-lasting neutropenia and diarrhea of late onset were
dose-limiting and defined the MTD at 0.12 mg/m2. Nausea
and vomiting were rare, neither neuro- nor renal toxic effects
were observed. BBR3464 showed a rapid distribution phase of
1 hour and a terminal half-life of several days. At 0.17 mg/m2
plasma Cmax and AUC on day 5 were higher than on day 1,
indicating drug accumulation. Approximately 10% of the
equivalent dose of BBR3464 (2.2%—13.4%) was recovered in a
24-hour urine collection.
Conclusions: The higher than expected incidence of neutro-
penia and GI toxicity might be related to the prolonged
half-life and accumulation of total and free Pt after daily
administrations. Lack of nephrotoxicity and the low urinary
excretion support the use of the drug without hydration.
The single intermittent schedule has been selected for clinical
development.
Key words: BBR3464, phase I, platinum analog, pharmaco-
kinetics
Introduction
BBR3464 is a charged (+4), triplatinum complex
(Figure 1) with notable preclinical characteristics. It is
approximately fourty- to eighty-fold more potent than
cisplatin (CDDP) on a molar-dose basis and is active in
vivo in CDDP-sensitive and resistant tumors, as well as
in insensitive xenografts. In addition, BBR3464 was
shown to be more active than CDDP in p53 mutant
tumors [1].
The characteristic DNA-interaction of BBR3464 re-
sults in an inhibition of DNA replication and RNA
transcription, with triggering of the apoptotic cascade
leading to cell death. Unlike cisplatin, BBR3464 leads to
prolonged tumor growth inhibition after discontinua-
tion of treatment, suggesting that the two drugs could
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Figure I. Chemical structure of BBR3464.
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differ significantly in their ability to perturb the cell
cycle [2].
As a distinctive feature, BBR3464 achieves a high
proportion of interstrand and intra-strand DNA adducts
in contrast to the effects of CDDP, which predominantly
produces predominantly the latter type of DNA damage.
While CDDP-damaged DNA is recognized by HMG-
proteins, the conformational changes resulting from
BBR3464 interaction with DNA are not. This observa-
tion might explain resistance to CDDP, and lack of
resistance to BBR3464 in tumors expressing mutations
of the p53 oncosuppressor gene [3].
The preclinical toxicology in mice, rats and dogs
treated on a single or daily x 5 refracted schedule
showed that target organs for BBR3464 toxicity were
bone marrow, resulting in leukopenia, and intestines,
while renal tubulopathy was only minimal or slight. A
slight pulmonary interstitial reaction, with fibroblast
proliferation and inflammatory infiltration, was ob-
served in mice and dogs. This unusual effect was more
extensive after intravenous bolus, given as a single or
weekly dose, than after slow infusion or every two-week
bolus [1]. The schedule dependency of the lung toxicity
prompted the clinical evaluation of a daily times 5
refracted schedule in addition to a single dose schedule.
The present report describes the clinical and pharmaco-
logical findings of a phase I investigation of the daily x 5
refracted schedule.
Patients and methods
Patients
Adult patients, aged 18-75 years, with histologically/cytologically con-
firmed advanced solid tumors, not amenable to conventional local or
systemic treatments, were candidates for this study. Eligibility criteria
also included a WHO performance status 4 2, life expectancy of > 3
months, adequate bone marrow (Hb > 10 g/dl; neutrophil count (ANC)
^ 2.0 x 109/l, platelet count > 100 x 109/l), liver (total bilirubin ^ 1.5 x
upper normal limit. ALATand/or ASAT <2.5 x upper normal limit,
unless due to tumor) and kidney (Creatinine Clearance >60 ml/min)
function. Patients could be eligible provided that: chemotherapy or
radiotherapy had not been given in the four weeks (six weeks in case of
mitomycin C, nitrosoureas or large-field radiotherapy) preceeding the
start of the treatment; they received a maximum cumulative dose of
800 mg/m2 of cisplatin; they had no clinically significant abnormalities
(NCIC-Common Toxicity Criteria (CTC) grade 3-4) of the cardio-
vascular system; no peripheral neuropathy ^ grade 2: no chronic
airways disorder or interstitial lung disease (dyspnea grade ^ 2
NCIC-CTC); no other coexisting medical problems of sufficient se-
verity to limit compliance with the study. Written informed consent
was obtained from all patients. For the purpose of data analysis
patients were considered heavily pretreated if they had at least one of
the following conditions: two or more prior chemotherapy regimens or
one prior chemotherapy regimen and radiotherapy.
double-dose step escalation, intra-patient dose escalation, and evalua-
tion of the number of grade 2 toxicities episodes over the total number
of cycles given. The maximum tolerated dose (MTD) was defined as
the dose at which one third or more of the patients (i.e., at least 2
patients) developed dose limiting toxicities (DLT) after the first cycle.
Escalation to the subsequent dose level was allowed only when the last
patient in the prior cohort had been observed for at least three weeks
following the administration of his/her first course. During the accel-
erated phase of the trial only one patient per cohort was treated until
one patient experienced a DLT or two patients experienced toxicities of
grade ~%1 according to the NCI-CTC. Definition of hematological
DLT included: CTC grade 4 thrombocytopenia and anemia, CTC
grade 4 neutropenia lasting 5*7 days, febrile neutropenia (ANC <0.5
x 109/l with fever either as two elevations of oral temperature > 38 °C
with one-hour interval or as single oral temperature >38.5°C). Non-
hematological DLT included all episodes of CTC grade 3 or grade 4
toxicity, with the exclusion of. nausea, vomiting and alopecia, pro-
longed (> 2 week duration) CTC grade 2; renal ( $ 6 0 ml/min), neuro-
logical, pulmonary, defined as a > 50% decrease of baseline value of
carbon monoxide diffusion capacity (CM DC).
After the first cycle, patients were eligible for retreatment if they
still met the entry criteria with a maximum delay of two weeks with
respect to the day planned for retreatment. The dose was decreased by
one level in instances of DLT and re-escalation at subsequent cycles
was not allowed.
Chemistry (including electrolytes, calcium, magnesium, creatinine,
total protein, albumin, bilirubin, alkaline phosphatase, glucose, trans-
aminases, uric acid, clotting factors, creatinine clearance and urinalyses)
were performed at least weekly, and more often in instances of toxicity.
Audiogram, ECG, and chest X-ray were done before therapy and
repeated when clinically indicated. CM DC was performed before
therapy and repeated before each cycle.
Toxicity was evaluated according to the CTC scale. Patients were
evaluable for hematological toxicity if at least weekly CBC counts with
differential were available for a minimum of three weeks. Patients were
evaluable for non-hematological toxicity after at least one day of treat-
ment.
At each dose level, safety analyses were performed on the total
number of evaluable cycles at that particular dose, regardless of
previous intrapatient dose escalations. In patients with measurable or
evaluable disease, tumor response was assessed after two cycles and
classified according to WHO criteria [5]. Responding patients or
patients with stable disease continued treatment until tumor progres-
sion or unacceptable toxicity whichever occurred first, while patients
with progressive disease went off study.
Drug administration
BBR was supplied by Novuspharma (Milano, Italy) as 0.5 mg/1 ml
vials to be stored at 2-8 °C. The requested daily amount of drug was
diluted and administered in 500 ml of normal saline as an intravenous
infusion over one hour for five consecutive days. Therapy was repeated
every 28 days. A pre- and post-hydration of 1000 ml of normal saline
given over one hour was administered on all days of treatment.
Antiemetic prophylaxis was not routinely administered. Intravenous
5-HT3 antagonists were prescribed in instances of vomiting on the
days of treatment. Oral thiethylperazine (6.5 mg t.i.d.) for nausea,
oral loperamide (4 mg after the first stool, then 2 mg every 2 hours up
to 12 hours after the last stool) was prescribed in case of diarrhea.
Finally, antibiotic prophylaxis (ciprofloxacin 500 mg b.i.d.) was
recommended in case of ANC of <0.5 x 109/l up to a ANC of
> 1.0 x 109/l.
Study design
The starting dose was 0.03 mg/m2/daily, corresponding to 1/10 of the
mouse equivalent MTD (MEMTD).
The dose was escalated according to the 4B \ersion of the acceler-
ated titration design for phase I studies [4], with single patient cohorts,
Pharmacokinetics
Pharmacokinetic studies of BBR3464 were performed in nine patients
on days 1 and 5 of the first cycle.
Blood samples (8 ml) from indwelling catheters in the arm con-
tralateral to the one with drug infusion were collected into heparinized
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tubes before and then at 60', 90', 2. 3,4.6,8.10, 24 hours from the start
of the infusion Additional samples were taken before the daily admin-
istration on days 3 and 4. and in selected cases on days 8 and 15. Urines
were collected on day 1 as eight-hour fractions, and two aliquots of 8 ml
each were taken from each fraction and stored at -20 °C or colder until
analysis.
Blood was immediately centrifuged after collection (2000 x g for 10
min at 4°C), plasma was separated from pellets and divided in two
aliquots. One aliquot of 1 ml was stored at -20 °C or colder for total Pt
analysis, and the other for preparation of plasma ultrafiltrate using
Millipore Ultrafree Filters (10,000 MW cut off) for free platinum
analysis. The filters were centrifuged at 4000 x g for 15 minutes at 4 °C
and the ultrafiltrate stored frozen at -20 °C or colder.
Total and free Pt concentrations in plasma, tissue and urine were
assessed by ICP-mass spectrometry (ICP-MS), and expressed as
BBR3464 equivalent concentrations.
A calibration curve in the range of platinum concentrations 0.01 —
200 ng/ml was prepared using the standard addition method by adding
Pt standard solution to plasma for the determination of total Pt and to
ultrapure water for the analysis of ultrafiltrate and urine. Linear
responses were observed in the working range with a correlation
coefficient r > 0.998. The quantitation limit (LOQ) was 0.01 ng/ml,
with an inter-days precision expressed as coefficient of variation (CV)
of 7.5%. The inter-assays CV determined at the upper point (200
ng/ml) of the calibration curve was 0.3%.
Biological samples were diluted in the range of concentrations of
the calibration curve to varying degrees (1/10 or 1/100 v/v) with
ultrapure water (Milli-Ro, Mill/Q, Millipore). Analytical procedure
and validation data will be reported in details in a separate paper. The
method has been validated according to international standards [6].
Pharmacokinetic parameters were derived from the individual
plasma BBR 3464 concentration-time profiles on days 1 and 5, accord-
ing to a non-compartmental approach using a general non-linear
fitting program [7]. Samples taken on days 8 and 15 were not included
in the evaluation of pharmacokinetic parameters.
Table I. Patient characteristics.
Total number of patients
Sex
Female
Male
Age (in years)
Median
Range
Prior theiapy
Chemotherapy alone
Chemo- and radiotherapy
Prior platinum compounds
Prior extensive therapy
Tumor types
Ovary
Colorectal
Non-small-cell lung
Other
14
10
4
51
41-70
11
3
8
10"
5
3
1
5
a
 > 2 chemotherapy regimens + radiotherapy.
Table 2 Number of evaluable patients and cycles per dose level.
Dose
level
1
2
3
4
5
Dose
(mg/nr/d)
0.03
0.06
0.12
0 14
0.17
Number of patients/cycles
Total
1/1
4/6
6/12
3/3
3/3
Entry
dose
1/1
2/4
5/10
3/3
3/3
Dose modified
1 /1 escalated from level 1;
1 /1 deescalated from level 3
112 escalated from level 2
Results
From November 1998 to September 1999, 14 patients
entered the trial, 5 in the accelerated dose escalation
phase and 9 in the standard phase. The patient charac-
teristics are reported in Table 1. Their median age was 51
years (range 41-70), and the median PS 0 (range 0-2).
All patients had already received chemotherapy, 8 of
them with cisplatin and/or carboplatin, with a median
of 131 days since the last course (range 31-490 days).
Table 2 lists the number of patients and cycles, either
initial or subsequent, at entry or modified dose, admin-
istered at each of the five dose levels, from 0.03 mg/m2 to
0.12 mg/m2. A total of 25 cycles were administered, of
which one at 0.06 and two at 0.12 mg/m2 were due to
intrapaticnt dose escalation from the previous dose
level, while an additional one at 0.06 mg/m2 was due
to dose-reduction because of severe abdominal pain,
nausea and vomiting.
Hematological toxicity
Neutropenia, which represented the main toxicity, was
dose-limiting and short-lasting. At all doses, the median
time to ANC nadir was 14 days (range 9-18 days) and
the median time to ANC recovery was 18 days (range
12-28 days). Time to recovery was longer at the higher
dose levels. No other hematological toxicities were ob-
served.
Together with diarrhea, neutropenia was one of the
toxicities on which dose escalation was based. The dose
was first doubled from 0.03-0.06 and then to 0.12
mg/m2. No DLTwas observed in the first three patients
treated at 0.12 mg/m2, with grade 1 neutropenia in one
out of two patients receiving 0.12 as entry dose and
grade 3 neutropenia in one patient already treated at
0.06 mg/m2. However, because of the occurrence of
diarrhea grade 1 in one patient and grade 2 in two
patients, the dose was cautiously escalated by 25% only
to 0.17 mg/m2. At this level, two of three patients
developed febrile neutropenia and grade 3 diarrhea,
prompting the assessment of an intermediate dose of
0.14 mg/m2 in three additional patients, all of whom had
received three prior chemotherapy regimens. Also at
this dose, two patients suffered a DLT consisting of
grade 4 diarrhea in one case and febrile neutropenia in
the other. The dose level of 0.12 mg/m2 was therefore
expanded by treating three further patients with a max-
imum of two prior chemotherapy regimens. One patient
developed grade 4 neutropenia and a second one febrile
neutropenia after the first cycle. Based on these findings,
and on the observations made in the other patients
initially treated at the same level, the dose of 0.12
mg/m2 was defined as the MTD.
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Table 3 Hematologic toxicity.
Dose
level
1
2
3
4
5
Dose
(mg/m2/d)
0.03
0.06
0.12
0.14
0.17
No.
of
cycles
1/0
2/4
5/7
3/0
3/0
Hemoglobin
at nadir
(g/dl),
median
(range)
13.2
10.3
(9-13.2)
9.1
(8.3-13.7)
8.8
(8.5-9.4)
10.8
(7.9-11.2)
Platelets
at nadir
(xlOO/mm3),
median
(range)
227
297
(243-412)
246
(128-420)
196
(139-225)
155
(129-247)
Neutrophiles at nadir (/mm
Median (range)
First cycle
2470
468, 1702
1800
(153-3141)
545
(81-2442)
370
(198-549)
Subsequent
cycles
-
1658
(864-2332)
392
(176-1536)
-
-
3)
Number of courses with
grade 3
First cycle
-
0
0
1
1
Subsequent
cycles
-
1
2
-
-
Number of courses with
grade 4
First cycle
-
1
2(1)"
1(1)
2(2)
Subsequent
cycles
-
0
4
-
-
a
 In brackets, number of cycles with febrile neutropenia.
Febrile neutropenia requiring hospitalization, also
because of concomitant diarrhea, was reported in four
occasions during the first cycle, at 0.12 and 0.14 mg/m2
in one case each, and in two out of three patients treated
at 0.17 mg/m2 (Table 3). Neutropenia was not cumula-
tive, and with a steep dose-response curve.
Thrombocytopenia was never observed while anemia
was only mild to moderate.
Non-hematological toxicity
Diarrhea, the main non hematological side effect, repre-
sented the other DLT with features of late appearance,
almost concomitantly with neutropenia, preceded by
abdominal cramps, and steep dose-response curve.
Drug-related diarrhea was first observed at 0.06 mg/m2,
became universal at the two highest dose levels and
could be controlled if loperamide was introduced early.
Possible risk-factors such as previous treatment with
5-FU, pelvic RT and Irinotecan could not be identified
because very few patients had received that type of
treatment before BBR3464 administration. Hospitaliza-
tion due to GI symptoms occurred in seven cycles:
diarrhea was the main symptom in three, and abdomi-
nal cramps in four cases.
Other toxicities included: paresthesia grade 1 in one
patient treated at 0.12 mg/m2; alopecia grade 1 in three
patients and grade 2 in one patient, all treated at 0.12
mg/m2; nausea grade 3 in one patient at 0.12 mg/m2 and
in one at 0.14 mg/m2; vomiting grade 3 in one patient at
0.12 mg/m2 and in one at 0.14 mg/m2.
Neither renal nor neurological toxicity were observed.
Antitumor response
No objective responses were observed. One patient with
pancreatic adenocarcinoma, pretreated with gemcitabine
and abdominal irradiation, presented a decrease of CA
19.9 after BBR at 0.12 mg/m2 with stabilization of tumor
recurrence for four months. One patient treated at
0.12 mg/m2 for ovarian carcinoma and tumor progres-
sion after paclitaxel, carboplatin and topotecan showed
a 50% decrease of CA125 levels with stabilization of
abdominal and pelvic recurrence. Treatment was dis-
continued after three courses because of cumulative
diarrhea and GI symptoms.
Pharmacokinetic results
The pharmacokinetics of BBR3464 on days 1 and 5 were
studied in nine patients treated at doses ranging from
0.03-0.17 mg/m2. Figure 2 shows the plasma pharmaco-
kinetic profile of total and free Pt of three patients
treated at 0.06 mg/m2 (1 patient) and 0.17 mg/m2 (2
patients). Both platinum species showed a similar plasma
disposition with a distribution phase of 1-2 hours fol-
lowed by a prolonged elimination phase longer than 24
Free
platinum
48 72
Time (hours)
120
0.17 mg/m2
0.17 mg/m2
0.06 mg/m2
Figure 2. Plasma levels of total and free platinum in three patients
receiving BBR3464 daily for five consecutive days.
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Table 4. Non-hematologic toxicity.
Dose level
1
2
3
4
5
Dose
0.03
0.06
0.12
0.14
0.17
Number of
cycles
1/1
4/6
6/12
3/3
3/3
Cycles with all grades toxicity
Nausea
0
1
6(1)
2(1)
1
i Vomiting
0
1
5(1)
2(1)
1
(grade 3. 4 or worst grade)
Diarrhea Abdominal Fatiaue
0
3
7(1)
3d)
3(2)
pain
2
1
4(1)
1
0
0
2
2
1
1(1)
Mucositis
0
0
3
1
1
Others
0
1 infection (1)
2 fever (1)
2 hypertension (1)
1 loss of appetite (1)
1 infection (1)
1 loss of appetite (1)
In brackets, number of cycles with grade 3-4 toxicity.
Table 5. Pharmacokinetic parameters of total and free Pt after treatment with BBR3464 daily for five consecutive days.
Patient
number
1
2
3
4
5
6
7
8
9
Dose
(mg/m2/d)
0.03
0.06
0.06
0.12
0.12
0.14
0.14
0.17
0.17
Total
Cma>
Day 1
1.5
3.9
3.7
6.9
8.1
7.3
10.2
11.1
11.2
platinum
(ng/ml)
Day 5
2.9
9 1
8.2
16.4
23.5
15.4
28.7
23.0
25.2
AUC(ng/ml/h)
Day 1
18
62
57
116
158
133
210
200
212
Day 5
42
_
148
318
466
270
502
465
489
D5/Dla
2.4
_
2.6
2.7
2.9
2.0
2.2
2.3
2.3
Free platinum
Cmax (ng/ml)
Day 1
0.02
0.13
0.12
0.22
0.31
0 36
0.45
0 40
0.43
Day 5
0.02
0.14
0.12
0.23
0.28
0.41
0.48
0.56
0.59
AUC (ng/ml/h)
Day 1
_
1.7
1.8
3.2
3.6
4.7
7.6
3.5
3.2
Day 5
_
_
35/Dl a
1.4 0.8
2.7 0.8
3.9
6.6
7.5
5.5
5.2
.1
.4
.0
.6
.6
Ratio AUC day 5 /AUC day 1.
hours. The planned sampling times, limited in many
cases to 24 and 72 hours after the end of the fifth
administration, did not allow a reliable evaluation of
the terminal half-life of total and free Pt. However, in 5
patients sampled longer than 72 hours, Pt levels were
still detectable on day 15, with concentrations of about
half the Cmax of both Pt species.
Table 5 reports Cmax, AUC(0-24) and the ratio of the
AUC(o_24) on days 5 and one for both the total and free
Pt species. At all dose levels, the values of Cmax and
AUC(o_24) of total Pt on day 5 were twice as high as
those on day 1. The Cmax and AUC of free Pt increased
1.5 times, and did so only at the highest dose level.
As shown in Figure 3 Cmax and AUC of total Pi
appeared to be linearly related to the dose (r - 0.950). A
similar relationship was also observed for free Pt (data
not shown).
Approximatively 10% of the dose administered was
recovered in the 24-hour urine fraction on day 1.
The Pt content was assessed in several tissues from
one patient with ovarian and breast tumors, who died 28
days after the first cycle at 0.14 mg/m2. Measurable Pt
levels were still present in tumor, ascites and several
other tissues, mainly kidney and lung (Table 6).
Discussion
The novel triplatinum complex BBR3464 was selected
for clinical development because of a promising preclin-
ical profile. In comparison with cisplatin, the different
interaction with DNA, the good antitumor activity in
several xenograft models irrespective of their pattern of
sensitivity/resistance to CDDP, and the forty-fold higher
potency of BBR3464 supports the concept that this new
drug may play an important role in humans.
Based on the observation that lung toxicity in mice
and dogs was more extensive after i.v. bolus than slow
infusion, we selected to evaluate a daily x 5 schedule in
humans, while other investigators performed an assess-
ment of the conventional single intermittent regimen [8].
An accelerated titration design version 4B could be
applied taking into account the toxicity information
provided by the already ongoing single intermittent
study.
The starting dose of 0.03 mg/m2/daily, corresponding
to 1/10 MEMTD and to a total dose of 0.15 mg/m2 per
cycle, could be doubled based on the absence of toxicity
in only one patient because the doses of 0.2 mg/m2 and
0.4 mg/m2 had already been tested and proven safe in the
ongoing trial adopting the single intermittent schedule.
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a
10-
7.5-
5 -
2.5-
0-
C
250 -|
200 -
150 -
100 -
5 0 -
0-
C
r=0.951;p<0001
O e)
O yS
So °
0.05 0.1 0.15
BBR3464 dose (mg/m2)
r - 0.950: p< 0.001
0.05 0.1 0.15
BBR3464 dose (mg/m2)
1
0.2
1
0.2
Table 6. Pt levels in tissues and in plasma 28 days after treatment with
BBR3464 (0.14 mg/nr/day).
Tissue Pt(ng/g)
Figure 3. Correlation between dose and both Cmax and AUC of total
platinum on day 1.
20
 n
48 96 144 192 240 288 336
Time (hours)
| * • Total Pl 0 Free Pi |
Figure 4. Plasma levels of total and free platinum in a patient who
received 0.14 mg/m2 of BBR3464 given daily for five consecutive days.
An intensive regimen of hydration and close assessment
of renal function was maintained in the study based
on the concern that the repeated administration could
cause cumulative renal effects. To rule out lung toxicity,
CMDC had to be checked after cycles 1 and 2.
The accelerated titration design version 4B proved
successful in speeding completion of the study and
reducing the number of patients treated at potentially
sub-therapeutic doses [4]. In fact, 5 dose levels were
assessed in a total of 14 patients over 25 evaluable cycles.
Overall, 12 patients and 18 cycles were evaluable at doses
corresponding to the MTD or higher, and only two
patients received non toxic, and potentially subthera-
peutic doses.
As observed for other platinum compounds [9], at all
dose levels of BBR3464 the clinical results qualitatively
Lung
Kidney
Brain
Liver
Heart
Intestine
Breast ca.
Ovarian ca.
Lymphnode
Ascite
Plasma (ultrafiltrate)
16
32
<0.01
10
16
8.5
3.4
3.7
8.5
3.1a
2.0a (0.09)a
a
 ng/ml.
confirmed the toxicology data, so that dose-limiting
toxicities were neutropenia and GI effects, and the re-
duced emetic potential and neurotoxicity were confirmed,
while no renal toxicity was observed. Based on these
findings, we conclude that BBR3464 can be adminis-
tered as an outpatient treatment, without hydration, and
without routine antiemetic prophylaxis.
Of note, the clinical results did not confirm significant
effects on the lung. The lack of significant alterations of
CMDC may depend on a variety of reasons, including
daily regimen, short duration of treatment and inter-
species differences. In view of the clinical development
of a single intermittent schedule and the potential role of
BBR3464 in the treatment of lung cancer, however, it is
recommended that the evaluation of lung function after
repeated administrations and a careful selection of pa-
tients should be performed in phase II studies. Neutro-
penia, appearing one week after treatment and recovering
in the following week, was the main DLTand defined the
MTD at 0.12 mg/m2/d. Late diarrhea, concomitant with
neutropenia, was the other DLT; this toxicity appeared
without identified risk-factors, and was responsive to an
aggressive treatment with loperamide. Both DLTs showed
a very steep dose-response curve, with a 0.06 mg/m2/d
dose interval between non toxic doses and the MTD.
The decision to apply only a 25% increase of the dose,
from 0.12 mg/m2 to 0.17 mg/m2 even though toxicity did
not reach the criteria of dose-limiting, was made on the
basis of the toxicity profile of the compound. In fact, the
occurrence of diarrhea increased significantly from 0.06
mg/m2 to 0.12 mg/m2 where it was reported in the first
three patients treated, suggesting that a subsequent
comparable increase of the dose might result in very
severe toxicity. Neutropenia and diarrhea were dose-
limiting also with the single intermittent schedule for
which a higher recommended dose of 1.1 mg/m2 was
established (H. Calvert, personal communication). The
intermittent dose schedule was selected for further de-
velopment and is undergoing extensive phase II clinical
evaluation.
Pharmacokinetic studies were performed by applying
a very sensitive ICP-MS assay, with a high sensitivity
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quantitation limit of 0.01 ng/ml, that allowed us to
determine total and free Pt concentrations even in pa-
tients receiving submilligram doses of BBR3464.
The available pharmacokinetic data achieved in the
whole range of the doses tested, from 0.03 to 0.17
mg/m2, indicate that BBR3464 has linear kinetics. Both
Cmax and AUC(0_24) increased proportionally with in-
creasing doses. The linear relationship is present for
both Pt species.
In this study, BBR3464 showed a slow elimination
rate from the plasma compartment, with an apparent
terminal half-life of several days. The prolonged termi-
nal phase explains the cumulation of total, but also (at
high dose) of ultrafiltered Pt, as shown by the increased
AUQo 24) d5/AUC(0_24) dl ratio in plasma. Of note, the
disposition of BBR3464 showed a quite limited inter-
patient variability.
The prolonged elimination half-life might explain the
reduced tolerability of the daily regimen compared to
the intermittent regimen and discourages its further
clinical development.
Another distinctive and clinically relevant pharmaco-
kinetic feature of BBR3464 is the reduced urinary ex-
cretion, accounting for only about 10% of the adminis-
tered dose in the 24-hour following treatment. The low
urinary excretion is in good agreement with the lack
of clinical renal toxicity. Based on these findings, we
conclude that BBR3464 can be administered as an out-
patient treatment, without hydration, and without rou-
tine antiemetic prophylaxis.
In the present study, all patients had normal liver
and renal function and information on pharmacokinetic
behaviour in case of liver or renal impairment could not
be provided. The reduced urinary excretion, however,
suggests that full doses of BBR3464 could be adminis-
tered also in instances of creatinine clearance in the
range of of 40-60 ml/min.
Tissue distribution was studied in one patient who
died 28 days after the first cycle at 0.14 mg/m2. Meas-
urable Pt levels were found in tumor, ascites and many
other tissues, but most notably in lungs and kidneys.
In conclusion, the results of this study have con-
firmed the preclinical data that the trinuclear platinum
complex BBR3464 is a new platinum analog with dose-
limiting neutropenia, diarrhea, no renal or neurotoxicity,
and decreased emetic potential.
The parallel pharmacokinetic study showed that the
drug has a prolonged elimination half-life, that may
partly explain the higher than expected toxicity of the
d x 5 schedule.
The pharmacokinetic data in patients are consistent
with preclinical observations in mice and dogs, where
BBR3464 plasma concentrations declined in a multi-
exponential fashion after i.v. administration, with a
rapid, short decline related to the distribution phase
followed by a slow and prolonged elimination phase,
with half-life of 27 hours (mouse) to 58 hours (dog) [1].
The prolonged permanence of BBR3464 in the sys-
temic circulation is likely due to low renal and hepatic
drug extraction ratios, and a high protein binding. The
unbound fraction of BBR3464 in patients approaches
2% over the entire observation interval. Differently from
cisplatin and carboplatin, most drug is bound to plasma
proteins at early times after the administration but the
free drug is available in the circulation for a long time
after dosing.
These human pharmacokinetics data have been and
are of great value in guiding the clinical development of
BBR3464.
The implementation of a 4B accelerated titration de-
sign, tailored to the clinical pattern of toxicity of the drug,
resulted in the rapid but safe completion of the study
with very few patients treated at doses below the MTD.
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